As NAMPT and NAPRT are the rate-limiting enzymes of the two NAD+ biosynthetic pathways (Figure 1A), neoplastic depletion of NAPRT can serve as a biomarker of NAMPT inhibitor-sensitive cancer. This evidence concerns the gene NAPRT and cancer.